Lantern Pharma Inc Stock Price, News & Analysis

Lantern Pharma (NASDAQ:LTRN) has publicly released predictBBB.ai™, a groundbreaking AI module for predicting blood-brain barrier (BBB) permeability with 94% accuracy, 95% sensitivity, and 89% specificity. The platform leverages billions of data points across millions of compounds to address a critical pharmaceutical challenge, as only 2-6% of small-molecule drugs successfully cross the blood-brain barrier.

The technology currently holds five of the top eleven positions on the Therapeutic Data Commons Leaderboard. The BBB technologies market is projected to grow from $1.4 billion in 2023 to $9.85 billion by 2032. Lantern is implementing a freemium business model to accelerate adoption while creating pathways for strategic collaborations across the pharmaceutical ecosystem.

Lantern Pharma (NASDAQ: LTRN) has successfully completed targeted enrollment for its Phase 2 HARMONIC™ clinical trial in Japan, enrolling 10 patients ahead of schedule across five clinical sites, including the National Cancer Center Japan. The trial evaluates LP-300 in combination with carboplatin and pemetrexed for never-smoker patients with non-small cell lung cancer (NSCLC).

The trial has shown promising initial results, with an 86% clinical benefit rate and 43% objective response rate among the first seven U.S. patients, including one patient achieving a durable complete response lasting nearly two years. The global trial aims to enroll approximately 90 patients across multiple regions, targeting a market opportunity estimated at over $4 billion annually.

Japan represents a strategically important region with 35-40% of NSCLC cases occurring in never-smokers, compared to 15% in Western populations. Additional clinical data from both Asian and U.S. patient cohorts is expected by the end of Q3 2025.

Lantern Pharma (NASDAQ: LTRN) has appointed Dr. Lee T. Schalop to its Board of Directors. Dr. Schalop brings over 20 years of combined experience in biotechnology leadership and financial markets, with expertise in precision neurooncology and clinical development.

Dr. Schalop notably co-founded Oncoceutics, Inc., which was successfully sold to Chimerix Inc. for $450 million in 2021. At Oncoceutics, he served in various senior roles including CEO, and the company later became part of Jazz Pharmaceuticals in a $935 million acquisition in 2025.

This strategic appointment aligns with Lantern Pharma's focus on AI-driven oncology drug development and its CNS-focused pipeline through subsidiary Starlight Therapeutics. Dr. Schalop's expertise in clinical development and strategic transactions is expected to support the company's mission in transforming cancer drug discovery through AI and machine learning.

Lantern Pharma (NASDAQ:LTRN) has reported a groundbreaking complete metabolic response in a heavily pre-treated lymphoma patient using LP-284 in its Phase 1 clinical trial. The 41-year-old patient, who had previously failed three aggressive treatment regimens including R-CHOP chemotherapy, CAR-T therapy, and bispecific antibody therapy, achieved complete response after just two 28-day cycles of LP-284.

The AI-guided drug development, powered by Lantern's RADR® platform, enabled the company to advance LP-284 from concept to clinical milestone in under three years at approximately $3 million. This success positions LP-284 to potentially address a critical need in the $4 billion global blood cancer market, particularly for DLBCL, which affects approximately 200,000 patients globally each year.

Lantern Pharma (NASDAQ:LTRN) has received a notice of allowance from the European Patent Office for LP-284, its AI-developed cancer therapy. The patent, extending through early 2039, covers the composition of matter for LP-284, which targets B-cell lymphomas and other B-cell malignancies.

LP-284, developed using Lantern's RADR® AI platform, is currently in Phase 1 clinical trials with potential completion in late 2025. The drug has received Orphan Drug Designations from the FDA for both mantle cell lymphoma (MCL) and high-grade B-cell lymphomas (HGBL). The therapy addresses a $4 billion annual market for blood cancers.

The development of LP-284 was notably efficient, achieving clinical trial readiness in under three years at a cost of $1.5 to $2.0 million. The patent complements existing protections in the US, Japan, India, and Mexico, with pending applications in other key markets.

Lantern Pharma (NASDAQ:LTRN) has launched an innovative AI-powered module within its RADR® platform to predict the effectiveness of combination cancer treatments. The module, trained on 221 clinical trials, focuses on DNA damaging agents (DDAs) and DNA repair inhibitors (DDRis), targeting a $50+ billion market growing at 8.5% annually through 2030.

The AI system has already demonstrated success by guiding an FDA-cleared Phase 1B/2 trial design combining LP-184 with olaparib for triple-negative breast cancer. The platform analyzes genomic, transcriptomic, and clinical data to predict drug synergies and identify optimal patient populations, potentially reducing development timelines and costs by one-third compared to traditional methods.

Key findings include an 80% positive outcome rate in non-PARP DDRi combinations, particularly with WEE1 inhibitors and platinum agents in TP53-mutated cancers.

Lantern Pharma (NASDAQ: LTRN) reports a remarkable clinical outcome from its Phase 2 HARMONIC trial, where a 70-year-old never-smoker with advanced non-small cell lung cancer (NSCLC) achieved a complete response using LP-300 with standard chemotherapy. The patient, who had previously failed three treatment lines including Keytruda, radiation, and Tagrisso, showed a 57% tumor reduction initially, followed by complete response in lung and adrenal gland lesions. After 21 treatment cycles over nearly two years, the patient maintains the response with no significant adverse reactions. This success is particularly significant for never-smokers with NSCLC, a growing patient population representing a $4+ billion market opportunity. Never-smoking NSCLC cases have increased from 15% in the 1970s to 33% in the 2000s, marking the fifth leading cause of cancer-related deaths globally.

Lantern Pharma (NASDAQ: LTRN) presented promising preclinical data for LP-184 in treating atypical teratoid rhabdoid tumors (ATRT), a rare pediatric brain cancer. The data, presented at SNO's Pediatric Conference by Johns Hopkins researchers, showed significant survival improvements in mouse models: 345% increase (89 vs 20 days) in the CHLA06 model and extended survival in the BT37 model (98 vs 68 days). LP-184 demonstrated potent anti-tumor activity across multiple ATRT subtypes, with IC50 values of 17.5-161 nM, strong blood-brain barrier penetrance, and no apparent toxicity. This data validates Lantern's FDA Rare Pediatric Disease Designation and supports their planned pediatric clinical trial, expected to begin in late 2025 or early 2026, following completion of ongoing adult solid tumor trials.

Lantern Pharma (NASDAQ: LTRN) reported Q1 2025 financial results and key developments. The company is nearing completion of LP-184 Phase 1a trial enrollment with 62-65 patients by June 2025. Their LP-300 HARMONIC Trial in never-smoker NSCLC patients showed promising preliminary results with 86% clinical benefit rate and 43% objective response rate. The company's RADR® AI platform expanded to 200 billion oncology-focused data points, with new modules for ADC development. Financial position remains stable with $19.7 million in cash and equivalents as of March 31, 2025, providing runway through May 2026. Q1 2025 showed reduced net loss of $4.5 million ($0.42/share) compared to $5.4 million ($0.51/share) in Q1 2024. R&D expenses decreased to $3.3 million from $4.3 million year-over-year, while G&A expenses remained stable at $1.5 million.